CytoDyn To Meet With Quest Clinical Research To Finalize Phase II Strategy For Novel AIDS Drug
Following a management meeting in San Francisco on June 7, representatives of CytoDyn, Inc. (Pink Sheets: CYDY) will be meeting with Principle Investigator Dr. Jay Lalezari at Quest Clinical Research to finalize the Company's strategy for a Phase II trial of Cytolin .
Emergent BioSolutions Initiates U.S. Phase II Trial Of Oral Typhoid Vaccine Candidate
Emergent BioSolutions Inc. (NYSE:EBS) announced that dosing of patients has begun in a U.S. Phase II clinical trial of the company's single-dose oral typhoid vaccine candidate. This randomized, double-blind, placebo-controlled, single-dose, dose-escalation trial is being conducted in healthy adults.
Predicting Irreparable Renal Ischemic Injury Using A Real-Time Marker In The Porcine Model
ORLANDO, FL (UroToday.com) - Dr. Cespedes presented his study looking at a real-time marker that could predict when permanent renal damage occurs during warm ischemic.Using a solitary kidney model, 15 pigs were subjected to warm ischemia times of 120, 150, and 180 minutes.
FTY720 Trial Continues Despite Death, UK
Drug manufacturer Novartis has reported that two people with MS taking the oral drug fingolimod (FTY720) in clinical trials experienced problems with infections, leading to a fatality in one case. The firm said the role of the medicine in the cases was unclear and that the trial will continue.
PSA Triggers For Intervention During Active Surveillance: Velocity Vs. Doubling Time Vs. General Linear Mixed Modeling
ORLANDO, FL (UroToday.com) - Active surveillance protocols are being implemented more frequently and are becoming a widely accepted management options for patients diagnosed with low risk disease.Klotz and colleagues from Toronto have lead the way in providing guidelines in these uncharted waters.
Micromet's BiTE Antibody Blinatumomab MT103 MEDI-538 Demonstrates Durable Responses In Patients With Relapsed Non-Hodgkin's Lymphoma
Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, presented an update of an ongoing phase 1 clinical trial for its BiTE(R) antibody blinatumomab (MT103/MEDI-538) at the 10th International Conference on Malignant Lymphomas (ICML) in Lugano, Switzerland.
New Data Show Potential Of Rasilez reg; To Protect Kidneys From Damage Independent Of Its Proven Ability To Lower Blood Pressure
Data published in this week's New England Journal of Medicine demonstrate that the first-in-class direct renin inhibitor Rasilez (aliskiren), known as Tekturna in the US, may have potential kidney-protective benefits that are independent of its already proven ability to provide powerful blood pressure reductions[1], [3].
ZymoGenetics And Merck Serono Initiate Second Phase 2 3 Clinical Study Of Atacicept In Lupus
ZymoGenetics, Inc. (NASDAQ:ZGEN) announced that its partner Merck Serono, a division of Merck KGaA, Darmstadt, Germany, initiated a Phase 2/3 trial of atacicept in patients with systemic lupus erythematosus (SLE). This study will evaluate the efficacy and safety of atacicept for the treatment of patients with SLE.
Vince And Associates Clinical Research Opens 50-Bed, Phase I Unit
Vince and Associates Clinical Research Inc., a leading independent provider of clinical trial services to the global pharmaceutical and biotechnology industry, announced the opening of a 50-bed, Phase I unit in order to keep up with the growing demand for its services.
Mentor Announces Completion Of Enrollment In Phase I Trial For Botulinum Toxin Type A In Patients With Cervical Dystonia
Mentor Corporation (NYSE:MNT), a leading supplier of medical products for the global aesthetics market, announced that it has taken the first steps toward entry into the U.S. neurological marketplace by completion of enrollment in the Phase I study in its U.